Updated long-term survival results from IMAGE 1, a phase II clinical trial evaluating a combination of IMM-101 and gemcitabine as first-line treatment for advanced pancreatic cancer, found that, in patients with metastatic disease, IMM-101 was associated with improving the probability of survival at 12 months to 24 percent, compared to 11.5 percent in patients receiving gemcitabine alone.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
